Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Viemed Healthcare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Viemed Healthcare şirketinin toplam hissedar öz sermayesi $121.2M ve toplam borcu $9.5M olup, bu da borç-öz sermaye oranını 7.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $163.9M ve $42.8M dir. Viemed Healthcare 'in FAVÖK'ü $17.0M faiz karşılama oranı 19 dur. Şirketin $8.8M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

7.8%

Borç/özkaynak oranı

US$9.49m

Borç

Faiz karşılama oranı	19x
Nakit	US$8.81m
Eşitlik	US$121.18m
Toplam yükümlülükler	US$42.77m
Toplam varlıklar	US$163.95m

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

Mar 07

Recent updates

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Apr 11

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

Mar 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VMD 'nin kısa vadeli varlıkları ( $45.0M ) kısa vadeli yükümlülüklerini ( $31.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: VMD şirketinin kısa vadeli varlıkları ( $45.0M ) uzun vadeli yükümlülüklerini ( $11.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VMD 'nin net borç/öz sermaye oranı ( 0.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: VMD 'nin borç/öz sermaye oranı son 5 yılda 12.6% seviyesinden 7.8% seviyesine düştü.

Borç Kapsamı: VMD 'nin borcu işletme nakit akışı ( 405.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: VMD 'in borcuna ilişkin faiz ödemeleri EBIT ( 19 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Viemed Healthcare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

Recent updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 7.8% to US$12.75

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Consensus EPS estimates fall by 19%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

CEO & Director exercised options and sold US$182k worth of stock

Third quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Price target increased by 15% to US$15.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

Insufficient new directors

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Viemed Healthcare: Comments On Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Healthcare Q2 2022 Earnings Preview

Viemed Announces Management Appointments

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare: New Bullish Trend Has Just Begun

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

Viemed Healthcare, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Viemed Healthcare EPS misses by $0.01, revenue in-line

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: US$10.80

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance

Investor sentiment improved over the past week

New 90-day high: US$9.83

Strong Execution By Insider-Owners Ensures Viemed's Growth

Viemed Healthcare Announces Recent Publication of Non-Invasive Ventilation Study

New 90-day low: US$7.92

Viemed Healthcare, Inc. (TSX:VMD) acquired 5% stake in VeruStat, Inc for approximately $0.6 million.

Viemed Healthcare, Inc. Appoints Sabrina Heltz to the Board and to Serve on the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Board

Third quarter 2020 earnings released: EPS US$0.072

Revenue beats expectations, earnings disappoint

Viemed Healthcare EPS misses by $0.02, beats on revenue

Market pulls back on stock over the past week

New 90-day low: US$8.01

New 90-day low - US$8.92

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin